Asked by: Ruth Cadbury (Labour - Brentford and Isleworth)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent discussions he has had with NHS England on screening new born children for Spinal Muscular Atrophy.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The UK National Screening Committee (UK NSC) has been working with partners to scope an in-service evaluation of newborn screening for spinal muscular atrophy (SMA) in real world National Health Services in the United Kingdom.
The research brief that will inform this in-service evaluation has now been published, and the call for applicants is live.
Results from the in-service evaluation, along with a new SMA screening modelling study, will inform any recommendation made by the UK NSC on whether to screen newborn babies for this condition.
Asked by: Ruth Cadbury (Labour - Brentford and Isleworth)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve screening of new born children for Spinal Muscular Atrophy.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The UK National Screening Committee (UK NSC) has been working with partners to scope an in-service evaluation of newborn screening for spinal muscular atrophy (SMA) in real world National Health Services in the United Kingdom.
The research brief that will inform this in-service evaluation has now been published, and the call for applicants is live.
Results from the in-service evaluation, along with a new SMA screening modelling study, will inform any recommendation made by the UK NSC on whether to screen newborn babies for this condition.
Asked by: Ruth Cadbury (Labour - Brentford and Isleworth)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to increase the number of mammograms available for women over the aged of 50 in West London.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England is committed to providing equitable access to breast screening services for eligible women aged 50 years old and over across the country, including in West London.
In West London, women aged 50 to 70 years old are invited for breast screening every three years as part of the NHS Breast Screening Programme, to the screening sites at the West of London Breast Screening Service (WOLBSS). There has been a surge in demand recently, following the disruption caused during the COVID-19 pandemic.
To address the increased demand for screening services post-COVID recovery, NHS England is working with the WOLBSS to improve appointment availability. This includes extending clinic hours, offering weekend clinics, investing in workforce recruitment and training, and targeting areas with lower screening uptake.
The information requested on average waiting times is not held centrally for screening mammograms.
Asked by: Ruth Cadbury (Labour - Brentford and Isleworth)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what the average waiting time is for women aged over 50 to receive a mammogram.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England is committed to providing equitable access to breast screening services for eligible women aged 50 years old and over across the country, including in West London.
In West London, women aged 50 to 70 years old are invited for breast screening every three years as part of the NHS Breast Screening Programme, to the screening sites at the West of London Breast Screening Service (WOLBSS). There has been a surge in demand recently, following the disruption caused during the COVID-19 pandemic.
To address the increased demand for screening services post-COVID recovery, NHS England is working with the WOLBSS to improve appointment availability. This includes extending clinic hours, offering weekend clinics, investing in workforce recruitment and training, and targeting areas with lower screening uptake.
The information requested on average waiting times is not held centrally for screening mammograms.
Asked by: Ruth Cadbury (Labour - Brentford and Isleworth)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to reduce the use of vapes by children under 16 years of age in the London Borough of Hounslow.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is taking progressive national-level action through the Tobacco and Vapes Bill to protect future generations from the harms of addiction and nicotine. The Bill includes strong measures to tackle youth vaping, including a ban on the sale of all vapes and nicotine products to children under the age of 18 years old and ending the free distribution of these products to anyone. The Bill will also ban the advertisement and sponsorship of all vapes and nicotine products and provides new powers to limit the flavours, packaging and changing where and how vapes and other nicotine products can be displayed.
The Bill also takes bold action to strengthen enforcement and tackle underage sales. This includes the introduction of new £200 fixed penalty notices to support Trading Standards to crack down on underage sales, and powers to introduce a licensing scheme for the retail sale of tobacco, vape and nicotine products. Alongside the Bill, the Government is investing over £100 million over five years to boost HM Revenue and Customs and Border Force enforcement capability. The Government is investing £10 million of new funding in Trading Standards this year to support the enforcement of illicit and underage tobacco and vape sales. This funding is being used to boost the Trading Standards workforce by recruiting over 80 new apprentices. Hounslow has been allocated a new apprentice.
Asked by: Ruth Cadbury (Labour - Brentford and Isleworth)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what estimate he has made of how many 12 to 16 year olds use vapes in (a) Hounslow (b) London.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England publishes estimates of the prevalence of vaping in children from the Smoking, Drinking and Drug Use among Young People in England Survey. This survey covers children in years seven to 11 in secondary school of whom the majority will be aged between 12 and 16 years old but some children aged 11 years old will also be included. Data on the use of vapes in children is not available at local authority level.
The latest figures for London are from the 2023 survey which showed that 4% of children were regular vapers, while 18% reported having ever tried vaping. The report is available at the following link:
Asked by: Ruth Cadbury (Labour - Brentford and Isleworth)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the powers available to local authorities to take enforcement action against shops unlawfully selling vapes.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Trading Standards Officers currently have a range of enforcement tools at their disposal to enforce age of sale restrictions and take a proportionate approach to enforcement that reflects the severity of the offence committed. When necessary, this includes prosecuting offenders which can result in courts imposing a fine of up to £2,500, and, in the case of repeat offences, applying for a restricted premises order or restricted sale order. £200 fixed penalty notices introduced by the Tobacco and Vapes Bill will complement existing sanctions and support Trading Standards to crack down on retailers selling to people underage.
To ensure that local authorities are provided with the appropriate powers to enforce measures in the Tobacco and Vapes Bill, provisions in the Bill give Trading Standards Officers investigatory powers set out in Schedule 5 of the Consumer Rights Act 2015. Future regulations relating to vaping product requirements will also provide appropriate powers for enforcement authorities to carry out their duties.
We will complete a post-implementation review of the measures in the Tobacco and Vapes Bill in due course.
Asked by: Ruth Cadbury (Labour - Brentford and Isleworth)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve access to treatments for long covid.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to ensuring that families have the support that they need. The Care Act 2014 requires local authorities to deliver a wide range of sustainable, high-quality care and support services, including support for carers, which can include parents.
Across the National Health Service in England, there are services supporting people with post-COVID syndrome, often described as long COVID. These services offer physical, cognitive, and psychological assessment, and, where appropriate, refer patients onto existing services for treatment and rehabilitation. Further information can be found via the NHS website, at the following link:
https://www.england.nhs.uk/coronavirus/post-covid-syndrome-long-covid/
The National Institute for Health and Care Research (NIHR) and the Medical Research Council (MRC) remain committed to funding high-quality research to understand the causes, consequences, and treatment for long COVID. We are actively exploring next steps for research in this area.
Between 2019/20 and 2023/24, through the NIHR and MRC, we have invested over £57 million on research into long COVID, with almost £40 million of this through two specific research calls on long COVID. The funded projects aim to improve our understanding of the diagnosis and underlying mechanisms of the disease and the effectiveness of both pharmacological and non-pharmacological therapies and interventions, as well as to evaluate the effectiveness of clinical care.
This includes funded clinical trials to test and compare different treatments such as antihistamines, anticoagulants, and anti-inflammatory medicines, as well as trials such as the approximately £1.5 million REGAIN trial funded through the NIHR. REGAIN is the first randomised trial to show a benefit from rehabilitation for people with long COVID, and the first high-quality evidence confirming the sustained clinical benefit and lack of harm with rehabilitation programmes for long COVID which combine exercise with behavioural support, to measure their effects on symptoms, health, and other outcomes.
The approximately £1.9 million CLoCk study, co-funded by the NIHR and the MRC, developed an agreed definition of long COVID in children and young people as well as the associated symptoms, which will help harmonise research and improve understanding of the condition.
Funding is available and we welcome funding applications for research into long COVID in both adults and children. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.
To support clinical leadership in this area, NHS England has worked in partnership with the British Society of Physical and Rehabilitation Medicine to develop a new Clinical Post-COVID Society to facilitate the ongoing sharing of best practice and to support people affected by long COVID. Further information about the society can be found at the following link:
https://www.clinicalpcs.org.uk
Asked by: Ruth Cadbury (Labour - Brentford and Isleworth)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of clinical research into treatments for long covid.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to ensuring that families have the support that they need. The Care Act 2014 requires local authorities to deliver a wide range of sustainable, high-quality care and support services, including support for carers, which can include parents.
Across the National Health Service in England, there are services supporting people with post-COVID syndrome, often described as long COVID. These services offer physical, cognitive, and psychological assessment, and, where appropriate, refer patients onto existing services for treatment and rehabilitation. Further information can be found via the NHS website, at the following link:
https://www.england.nhs.uk/coronavirus/post-covid-syndrome-long-covid/
The National Institute for Health and Care Research (NIHR) and the Medical Research Council (MRC) remain committed to funding high-quality research to understand the causes, consequences, and treatment for long COVID. We are actively exploring next steps for research in this area.
Between 2019/20 and 2023/24, through the NIHR and MRC, we have invested over £57 million on research into long COVID, with almost £40 million of this through two specific research calls on long COVID. The funded projects aim to improve our understanding of the diagnosis and underlying mechanisms of the disease and the effectiveness of both pharmacological and non-pharmacological therapies and interventions, as well as to evaluate the effectiveness of clinical care.
This includes funded clinical trials to test and compare different treatments such as antihistamines, anticoagulants, and anti-inflammatory medicines, as well as trials such as the approximately £1.5 million REGAIN trial funded through the NIHR. REGAIN is the first randomised trial to show a benefit from rehabilitation for people with long COVID, and the first high-quality evidence confirming the sustained clinical benefit and lack of harm with rehabilitation programmes for long COVID which combine exercise with behavioural support, to measure their effects on symptoms, health, and other outcomes.
The approximately £1.9 million CLoCk study, co-funded by the NIHR and the MRC, developed an agreed definition of long COVID in children and young people as well as the associated symptoms, which will help harmonise research and improve understanding of the condition.
Funding is available and we welcome funding applications for research into long COVID in both adults and children. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.
To support clinical leadership in this area, NHS England has worked in partnership with the British Society of Physical and Rehabilitation Medicine to develop a new Clinical Post-COVID Society to facilitate the ongoing sharing of best practice and to support people affected by long COVID. Further information about the society can be found at the following link:
https://www.clinicalpcs.org.uk
Asked by: Ruth Cadbury (Labour - Brentford and Isleworth)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to improve the treatments available for brain tumours in west London.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government has invested in new lifesaving and life-improving research, supporting those diagnosed and living with brain tumours. In September 2024, the National Institute for Health and Care Research (NIHR) announced new research funding opportunities for brain cancer research, spanning both adult and paediatric populations. This includes a national NIHR Brain Tumour Research Consortium, to ensure the most promising research opportunities are made available to adult and child patients.
The National Cancer Plan will include further details on how we will improve outcomes, including treatment options, for all cancer patients including those with brain tumours.